

TABLE 2-continued

Inhibitor	Concentration (mM)	Relative Activity (%)	
Ethylenediaminetetraacetate (EDTA)	1	1	5
Phosphoramidon	0.1	4	
Phenylmethanesulfonyl fluoride (PMSF)	1	8	
Chymostatin	0.01	25	10
Thiorphan	0.1	2	

## SEQUENCE LISTING

## ( 1 ) GENERAL INFORMATION:

( i i i ) NUMBER OF SEQUENCES: 1

## ( 2 ) INFORMATION FOR SEQ ID NO:1:

## ( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 38 amino acids
- ( B ) TYPE: amino acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

## ( i x ) FEATURE:

- ( A ) NAME/KEY: Disulfide-bond
- ( B ) LOCATION: 1..15

## ( i x ) FEATURE:

- ( A ) NAME/KEY: Disulfide-bond
- ( B ) LOCATION: 3..11

## ( i x ) FEATURE:

- ( A ) NAME/KEY: Cleavage-site
- ( B ) LOCATION: 21..22

## ( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His
1          5          10
Leu Asp Ile Ile Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly
20          25          30
Leu Gly Ser Pro Arg Ser
35

```

What is claimed is:

1. A method of converting big endothelin-1 to endothelin-1 comprising:

contacting said big endothelin-1 with isolated, purified human apolipoprotein B having a proteolytic activity for cleaving said big endothelin-1 to produce said endothelin-1.

\* \* \* \* \*

60

65